Skip to content
Company Analysis

Boston Scientific Corporation BSX

A comprehensive view of key metrics, scores, and financial health for Boston Scientific Corporation

Overview of Boston Scientific Corporation

BSX NYQ
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Large Cap
Boston Scientific Corporation (BSX), is a Large Cap company, in the Medical Devices industry, last closed at $46.91, about 50.4% overvalued vs fair value, -53.0% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth 19.9% ROE 12.6% Gross Margin 69.0%
USD 46.91
-0.55%
(Delayed)
• Vol 90d: 53.0%
Market Cap
$70.11B
Enterprise Value
$80.48B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 89%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.bostonscientific.c...
HQ Marlborough, MA
Employees 59,000
Fiscal year Dec 31

Next Events

Earnings Jul 29 Call: Jul 29

Fair Value Snapshot

Bear Base Bull
$21
$23
$26
Current: $46.91 -50% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$20.1B
19.9%%
Gross Profit
$13.9B
20.6%%
Operating Income (GAAP)
$4.0B
32.3%%
EBITDA
$3.7B
-3.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
69.0%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$230.0M
9.7% of Free Cash Flow

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
2/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Boston Scientific Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
77
/100
Strong
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
86
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing BSX's balance between Growth (31.2%), Profitability (37.4%), and Safety (31.4%). Growth 31% Safety 31% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

70th percentile vs peers
70
Key Signals
Rev Growth YoY 19.9% 76p Revenue CAGR 3Y 16.5% 70p EPS CAGR 3Y 22.0% 75p EPS Growth YoY 16.3% 45p TSR 79.5% 88p
Strengths
  • FCF Margin in top 20% of peers (18.2%, 92th percentile)
  • Operating Margin in top 20% of peers (19.8%, 90th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (1.30, 84th percentile)
  • Superior capital returns - 2 return metrics above peer median
Risks

No significant risks identified for this axis.

Profitability

84th percentile vs peers
84
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

70th percentile vs peers
71
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Boston Scientific Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$23.28
- - -
-50.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000